MA31008B1 - Polymorphes d'un antagoniste du recepteur mglur5 - Google Patents
Polymorphes d'un antagoniste du recepteur mglur5Info
- Publication number
- MA31008B1 MA31008B1 MA32012A MA32012A MA31008B1 MA 31008 B1 MA31008 B1 MA 31008B1 MA 32012 A MA32012 A MA 32012A MA 32012 A MA32012 A MA 32012A MA 31008 B1 MA31008 B1 MA 31008B1
- Authority
- MA
- Morocco
- Prior art keywords
- mglur5 receptor
- polymorphs
- receptor antagonist
- receptor
- acute
- Prior art date
Links
- 101150087728 Grm5 gene Proteins 0.000 title abstract 2
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- -1 4-FLUORO-PHENYL Chemical class 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000001914 Fragile X syndrome Diseases 0.000 abstract 1
- 241000196323 Marchantiophyta Species 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 229910021653 sulphate ion Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DES SELS DE MONO-SULFATE ET D'HÉMI-SULFATE DE 2-CHLORO-4-[1-(4-FLUORO-PHÉNYL)-2,5-DIMÉTHYL-1H-IMIDAZOL-4-YLÉTHYNYL]-PYRIDINE, DES FORMES CRISTALLINES ET AMORPHES DE CEUX-CI AINSI QUE LEUR UTILISATION DANS DES PRÉPARATIONS PHARMACEUTIQUES. LES PRÉSENTS COMPOSÉS SONT ACTIFS SUR LE RÉCEPTEUR MGLUR5 POUR TRAITER DES MALADIES ASSOCIÉES À CE RÉCEPTEUR, TELLES QUE LES TROUBLES NEUROLOGIQUES AIGUS ET/OU CHRONIQUES, ET NOTAMMENT L'ANXIÉTÉ, OU POUR TRAITER LA DOULEUR CHRONIQUE ET AIGUË OU OFFRIR UNE PROTECTION CONTRE LES ATTEINTES HÉPATIQUES, L'INSUFFISANCE INDUITE PAR UN MÉDICAMENT OU UNE MALADIE, L'INCONTINENCE URINAIRE, L'OBÉSITÉ, LE SYNDROME DE L'X FRAGILE OU L'AUTISME.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87639806P | 2006-12-21 | 2006-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31008B1 true MA31008B1 (fr) | 2009-12-01 |
Family
ID=39186951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32012A MA31008B1 (fr) | 2006-12-21 | 2009-06-17 | Polymorphes d'un antagoniste du recepteur mglur5 |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US8063076B2 (fr) |
| EP (1) | EP2125779B1 (fr) |
| JP (1) | JP5405311B2 (fr) |
| KR (1) | KR101148580B1 (fr) |
| CN (1) | CN101568531B (fr) |
| AR (1) | AR064654A1 (fr) |
| AU (1) | AU2007336369B2 (fr) |
| CA (1) | CA2673444C (fr) |
| CL (1) | CL2007003695A1 (fr) |
| CO (1) | CO6210731A2 (fr) |
| CY (1) | CY1117810T1 (fr) |
| DK (1) | DK2125779T3 (fr) |
| EC (1) | ECSP099431A (fr) |
| ES (1) | ES2577391T3 (fr) |
| HR (1) | HRP20160950T1 (fr) |
| HU (1) | HUE029324T2 (fr) |
| IL (1) | IL199181A (fr) |
| MA (1) | MA31008B1 (fr) |
| MX (1) | MX2009006694A (fr) |
| MY (1) | MY148217A (fr) |
| NO (1) | NO342451B1 (fr) |
| NZ (1) | NZ577440A (fr) |
| PE (1) | PE20081484A1 (fr) |
| PL (1) | PL2125779T3 (fr) |
| PT (1) | PT2125779T (fr) |
| RS (1) | RS54853B1 (fr) |
| RU (1) | RU2460728C2 (fr) |
| SI (1) | SI2125779T1 (fr) |
| TW (1) | TWI347320B (fr) |
| UA (1) | UA96970C2 (fr) |
| WO (1) | WO2008074697A1 (fr) |
| ZA (1) | ZA200904289B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5405311B2 (ja) | 2006-12-21 | 2014-02-05 | エフ．ホフマン−ラ ロシュ アーゲー | ｍＧｌｕＲ５受容体アンタゴニストの多形 |
| US20120039999A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| MX2013010698A (es) | 2011-03-18 | 2014-02-17 | Novartis Ag | Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson. |
| EP2837631A1 (fr) | 2013-08-14 | 2015-02-18 | Merck & Cie | Nouveau sel stable d'acide 5,10-méthylène-(6R)-tétrahydrofolique |
| GB201317022D0 (en) * | 2013-09-25 | 2013-11-06 | Addex Pharmaceuticals Sa | Polymorphs |
| AU2015205753A1 (en) | 2014-01-10 | 2016-07-21 | Birdie Biopharmaceuticals Inc. | Compounds and compositions for treating HER2 positive tumors |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN118515666A (zh) | 2017-04-27 | 2024-08-20 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| IL322310A (en) * | 2020-06-05 | 2025-09-01 | Noema Pharma Ag | Methods for treating multiple sclerosis complex |
| MX2023001288A (es) * | 2020-07-30 | 2023-04-28 | Noema Pharma Ag | Metodos de tratamiento de la neuralgia del trigemino. |
| CN120459099A (zh) * | 2025-06-17 | 2025-08-12 | 北京大学成都前沿交叉生物技术研究院 | mGlu5抑制剂在治疗或预防非酒精性脂肪肝病和/或肥胖、改善瘦素敏感性方面的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3303199A (en) * | 1963-07-15 | 1967-02-07 | Geigy Chem Corp | Certain imidazolone derivatives and process for making same |
| US3341548A (en) * | 1964-04-29 | 1967-09-12 | Hoffmann La Roche | Nitroimidazoles and their preparation |
| DE2035905A1 (de) | 1970-07-20 | 1972-02-03 | Chemische Fabrik Stockhausen & Cie.,4150Krefeld | Imidazolverbindungen und deren Herstellungsverfahren |
| CA1174673A (fr) | 1981-02-27 | 1984-09-18 | Walter Hunkeler | Imidazodiazepines |
| US4508560A (en) * | 1981-11-11 | 1985-04-02 | Ciba Geigy Corporation | Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use |
| US4711962A (en) * | 1984-10-18 | 1987-12-08 | Stauffer Chemical Company | Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles |
| KR0163595B1 (ko) | 1989-06-30 | 1998-12-01 | 미리암디, 메코너헤이 | 치환된 이미다졸 |
| TW544448B (en) | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| HRP20000079A2 (en) | 1997-08-14 | 2000-12-31 | Hoffmann La Roche | Heterocyclic vinylethers against neurological disorders |
| JP4815083B2 (ja) | 1999-08-31 | 2011-11-16 | メルク・シャープ・エンド・ドーム・コーポレイション | 複素環化合物およびそれの使用方法 |
| JP5154728B2 (ja) | 2000-07-24 | 2013-02-27 | クレニツキー・ファーマシューティカルズ，インコーポレイテッド | 神経栄養活性を有する置換５−アルキニルピリミジン |
| ATE288898T1 (de) | 2000-12-04 | 2005-02-15 | Hoffmann La Roche | Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten |
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| EP1458385A4 (fr) * | 2001-12-19 | 2005-12-21 | Merck & Co Inc | Imidazoles substitues par heteroaryle modulateurs du recepteur metabotropique du glutamate de type 5 |
| TWI292318B (en) | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
| UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| US7091222B2 (en) * | 2003-07-03 | 2006-08-15 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| US7452909B2 (en) | 2003-09-04 | 2008-11-18 | Hoffman-La Roche Inc. | Imidazole derivatives |
| AU2005250101B2 (en) * | 2004-06-01 | 2011-08-25 | F. Hoffmann-La Roche Ag | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mGlu5 receptor antagonists |
| JP5405311B2 (ja) | 2006-12-21 | 2014-02-05 | エフ．ホフマン−ラ ロシュ アーゲー | ｍＧｌｕＲ５受容体アンタゴニストの多形 |
-
2007
- 2007-12-11 JP JP2009541986A patent/JP5405311B2/ja active Active
- 2007-12-11 KR KR1020097012810A patent/KR101148580B1/ko active Active
- 2007-12-11 AU AU2007336369A patent/AU2007336369B2/en active Active
- 2007-12-11 MX MX2009006694A patent/MX2009006694A/es active IP Right Grant
- 2007-12-11 WO PCT/EP2007/063721 patent/WO2008074697A1/fr not_active Ceased
- 2007-12-11 HR HRP20160950TT patent/HRP20160950T1/hr unknown
- 2007-12-11 DK DK07857408.4T patent/DK2125779T3/en active
- 2007-12-11 CN CN2007800475969A patent/CN101568531B/zh active Active
- 2007-12-11 SI SI200731792A patent/SI2125779T1/sl unknown
- 2007-12-11 UA UAA200907474A patent/UA96970C2/ru unknown
- 2007-12-11 PL PL07857408.4T patent/PL2125779T3/pl unknown
- 2007-12-11 ES ES07857408.4T patent/ES2577391T3/es active Active
- 2007-12-11 NZ NZ577440A patent/NZ577440A/en unknown
- 2007-12-11 CA CA2673444A patent/CA2673444C/fr active Active
- 2007-12-11 RS RS20160461A patent/RS54853B1/sr unknown
- 2007-12-11 RU RU2009123135/04A patent/RU2460728C2/ru active
- 2007-12-11 HU HUE07857408A patent/HUE029324T2/en unknown
- 2007-12-11 EP EP07857408.4A patent/EP2125779B1/fr active Active
- 2007-12-11 MY MYPI20092393A patent/MY148217A/en unknown
- 2007-12-11 PT PT78574084T patent/PT2125779T/pt unknown
- 2007-12-14 PE PE2007001802A patent/PE20081484A1/es not_active Application Discontinuation
- 2007-12-17 US US11/957,515 patent/US8063076B2/en active Active
- 2007-12-19 TW TW096148786A patent/TWI347320B/zh active
- 2007-12-19 CL CL200703695A patent/CL2007003695A1/es unknown
- 2007-12-21 AR ARP070105822A patent/AR064654A1/es not_active Application Discontinuation
-
2009
- 2009-06-04 IL IL199181A patent/IL199181A/en active IP Right Grant
- 2009-06-05 CO CO09058653A patent/CO6210731A2/es not_active Application Discontinuation
- 2009-06-15 EC EC2009009431A patent/ECSP099431A/es unknown
- 2009-06-17 MA MA32012A patent/MA31008B1/fr unknown
- 2009-06-18 ZA ZA200904289A patent/ZA200904289B/xx unknown
- 2009-06-19 NO NO20092357A patent/NO342451B1/no unknown
-
2011
- 2011-10-14 US US13/273,266 patent/US8329912B2/en active Active
-
2016
- 2016-07-19 CY CY20161100705T patent/CY1117810T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31008B1 (fr) | Polymorphes d'un antagoniste du recepteur mglur5 | |
| MA30340B1 (fr) | Nouveaux composes | |
| EP1838320A4 (fr) | Antagonistes de cxcr4 pour le traitement de troubles medicaux | |
| MA33053B1 (fr) | Inhibiteurs de la poly(adp-ribose) polymerase (parp) | |
| EP1551369A4 (fr) | Therapie de combinaison pour le traitement de troubles fibrosants | |
| MA28481B1 (fr) | Dérivés d'imidazole pour le traitement de troubles neurodégénératifs | |
| MX2007005570A (es) | Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos. | |
| MA32804B1 (fr) | Antagonistes d'isonicotinamide des récepteurs de l'orexine | |
| TNSN08027A1 (en) | Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use of same | |
| EP2331095A4 (fr) | Certains inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci | |
| MA31260B1 (fr) | 3-imidazolyl-indoles pour le traitement de maladies proliferatives | |
| EP2096919A4 (fr) | Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse | |
| EP2076122A4 (fr) | Dérivés d'alcynylphényle pour traiter les maladies et les affections ophtalmiques | |
| MA33593B1 (fr) | Composés hétérocycliques et leurs utilisations | |
| MA31707B1 (fr) | Dérivés de benzimidazole et d'indole substitués par de l'oxadiazole et oxazole comme inhibiteurs de dgat1 | |
| NZ597648A (en) | Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats | |
| WO2007087151A3 (fr) | Méthode de traitement d'un dysfonctionnement cognitif | |
| EP2056848A4 (fr) | Utilisation d'extraits pour le traitement de troubles viraux | |
| BRPI0517438A (pt) | composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica | |
| EP1929291A4 (fr) | Therapie par estriol pour maladie des troubles auto-immuns et neurodegeneratifs | |
| EP2196206A4 (fr) | Remède destiné à soulager des troubles cutanés comprenant un dérivé de morphinane ou l'un de ses sels d'addition d'acide acceptables sur le plan pharmacologique en tant que principe actif | |
| EP2328584A4 (fr) | Traitement de troubles neurologiques à l'aide d'huperzine | |
| MA30901B1 (fr) | Therapie de combinaison sequentielle | |
| BRPI0617673C1 (pt) | composições de inibidores de fosfodiesterase do tipo iv | |
| EP1855682A4 (fr) | Formes posologiques d'aminopterine et methodes pour troubles inflammatoires |